Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 316 of the 322 references it cites were found in a registry or an index.

Targeting Glucose Metabolism Enzymes in Cancer Treatment: Current and Emerging Strategies

Open access

Abstract

Reprogramming of glucose metabolism provides sufficient energy and raw materials for the proliferation, metastasis, and immune escape of cancer cells, which is enabled by glucose metabolism-related enzymes that are abundantly expressed in a broad range of cancers. Therefore, targeting glucose metabolism enzymes has emerged as a promising strategy for anticancer drug development. Although several glucose metabolism modulators have been approved for cancer treatment in recent years, some limitations exist, such as a short half-life, poor solubility, and numerous adverse effects. With the rapid development of medicinal chemicals, more advanced and effective glucose metabolism enzyme-targeted anticancer drugs have been developed. Additionally, several studies have found that some natural products can suppress cancer progression by regulating glucose metabolism enzymes. In this review, we summarize the mechanisms underlying the reprogramming of glucose metabolism and present enzymes that could serve as therapeutic targets. In addition, we systematically review the existing drugs targeting glucose metabolism enzymes, including small-molecule modulators and natural products. Finally, the opportunities and challenges for glucose metabolism enzyme-targeted anticancer drugs are also discussed. In conclusion, combining glucose metabolism modulators with conventional anticancer drugs may be a promising cancer treatment strategy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers14194568

Cites

316 of 316 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Reprogramming of glucose metabolism in cancer cells. (A) Glucose metabolism in normal cells; (B) glucose metabolism in cancer cells. Cellular uptake of glucose is followed by a series of reactions to transform glucose to pyruvate. Then, glucose enters the TCA cycle or is converted to lactate. Enzymes or pathways predominant in cancer cells are shown in bold red. Created with BioRender.com (accessed on 22 August 2022). Abbreviations: 1,3 BPG, 1,3-bisphosphoglycerate; 2-PG, 2-phosphoglycerate; 3-PG, 3-phosphoglycerate; α-KG, α-ketoglutarate; AcCoA, acetyl coenzyme A; ADP, adenosine diphosphate; ALDO, aldolase; ATP, adenosine triphosphate; DHAP, dihydroxyacetone-phosphate; ENO, enolase; F-1,6-BP, fructose-1,6-bisphosphate; F-2,6-BP, fructose-2,6-bisphosphate; F-6-P, fructose-6-phosphate; FAS, fatty acid synthesis; G-3-P, glyceraldehyde-3-phosphate; G-6-P, glucose-6-phosphate; HK, hexokinase; LDH, lactate dehydrogenase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GCK, glucokinase; GLUT, glucose transporter; glycerol-3P, glycerol-3-phosphate; GPI, glucose-6-phosphate isomerase; MCT, monocarboxylate transporter; OAA, oxaloacetate; PEP, phosphoenolpyruvate; PFK1, phosphofructokinase 1; PFKFB, 6-phosphofructo 2-kinase/fructose-2,6-bisphosphatase; PGAM1, phosphoglycerate mutase 1; PGK1, phosphoglycerate kinase 1; PK, pyruvate kinase; PPP, pentose phosphate pathway; TCA, tricarboxylic acid; TPI, triosephosphate isomerase.
Figure 1 Reprogramming of glucose metabolism in cancer cells. (A) Glucose metabolism in normal cells; (B) glucose metabolism in cancer cells. Cellular uptake of glucose is followed by a series of reactions to transform glucose to pyruvate. Then, glucose enters the TCA cycle or is converted to lactate. Enzymes or pathways predominant in cancer cells are shown in bold red. Created with BioRender.com (accessed on 22 August 2022). Abbreviations: 1,3 BPG, 1,3-bisphosphoglycerate; 2-PG, 2-phosphoglycerate; 3-PG, 3-phosphoglycerate; α-KG, α-ketoglutarate; AcCoA, acetyl coenzyme A; ADP, adenosine diphosphate; ALDO, aldolase; ATP, adenosine triphosphate; DHAP, dihydroxyacetone-phosphate; ENO, enolase; F-1,6-BP, fructose-1,6-bisphosphate; F-2,6-BP, fructose-2,6-bisphosphate; F-6-P, fructose-6-phosphate; FAS, fatty acid synthesis; G-3-P, glyceraldehyde-3-phosphate; G-6-P, glucose-6-phosphate; HK, hexokinase; LDH, lactate dehydrogenase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GCK, glucokinase; GLUT, glucose transporter; glycerol-3P, glycerol-3-phosphate; GPI, glucose-6-phosphate isomerase; MCT, monocarboxylate transporter; OAA, oxaloacetate; PEP, phosphoenolpyruvate; PFK1, phosphofructokinase 1; PFKFB, 6-phosphofructo 2-kinase/fructose-2,6-bisphosphatase; PGAM1, phosphoglycerate mutase 1; PGK1, phosphoglycerate kinase 1; PK, pyruvate kinase; PPP, pentose phosphate pathway; TCA, tricarboxylic acid; TPI, triosephosphate isomerase.CC BY · PubMed Central
Figure 2 Drugs targeting glucose metabolism in cancer cells. Reprogramming of glucose metabolism provides many potential targets for cancer therapy. Created with BioRender.com (accessed on 22 August 2022). Abbreviations: 1,3 BPG, 1,3-bisphosphoglycerate; 2-PG, 2-phosphoglycerate; 3-PG, 3-phosphoglycerate; ADP, adenosine diphosphate; ALDO, aldolase; ATP, adenosine triphosphate; DHAP, dihydroxyacetone-phosphate; ENO, enolase; F-1,6-BP, fructose-1,6-bisphosphate; F-2,6-BP, fructose-2,6-bisphosphate; F-6-P, fructose-6-phosphate; G-3-P, glyceraldehyde-3-phosphate; G-6-P, glucose-6-phosphate; HK, hexokinase; LDH, lactate dehydrogenase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GLUT, glucose transporter; GPI, glucose-6-phosphate isomerase; MCT, monocarboxylate transporter; PEP, phosphoenolpyruvate; PFK1, phosphofructokinase-1; PFKFB, 6-phosphofructo 2-kinase/fructose-2,6-bisphosphatase; PGAM1, phosphoglycerate mutase 1; PGK1, phosphoglycerate kinase 1; PK, pyruvate kinase; TPI, triosephosphate isomerase.
Figure 2 Drugs targeting glucose metabolism in cancer cells. Reprogramming of glucose metabolism provides many potential targets for cancer therapy. Created with BioRender.com (accessed on 22 August 2022). Abbreviations: 1,3 BPG, 1,3-bisphosphoglycerate; 2-PG, 2-phosphoglycerate; 3-PG, 3-phosphoglycerate; ADP, adenosine diphosphate; ALDO, aldolase; ATP, adenosine triphosphate; DHAP, dihydroxyacetone-phosphate; ENO, enolase; F-1,6-BP, fructose-1,6-bisphosphate; F-2,6-BP, fructose-2,6-bisphosphate; F-6-P, fructose-6-phosphate; G-3-P, glyceraldehyde-3-phosphate; G-6-P, glucose-6-phosphate; HK, hexokinase; LDH, lactate dehydrogenase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GLUT, glucose transporter; GPI, glucose-6-phosphate isomerase; MCT, monocarboxylate transporter; PEP, phosphoenolpyruvate; PFK1, phosphofructokinase-1; PFKFB, 6-phosphofructo 2-kinase/fructose-2,6-bisphosphatase; PGAM1, phosphoglycerate mutase 1; PGK1, phosphoglycerate kinase 1; PK, pyruvate kinase; TPI, triosephosphate isomerase.CC BY · PubMed Central
Figure 3 The chemical structures of drugs targeting glucose transferase.
Figure 3 The chemical structures of drugs targeting glucose transferase.CC BY · PubMed Central
Figure 4 The chemical structures of drugs targeting hexokinase.
Figure 4 The chemical structures of drugs targeting hexokinase.CC BY · PubMed Central
Figure 5 The chemical structures of drugs targeting phosphofructokinase.
Figure 5 The chemical structures of drugs targeting phosphofructokinase.CC BY · PubMed Central
Figure 6 The chemical structures of drugs targeting pyruvate kinase.
Figure 6 The chemical structures of drugs targeting pyruvate kinase.CC BY · PubMed Central
Figure 7 The chemical structures of drugs targeting lactate dehydrogenase.
Figure 7 The chemical structures of drugs targeting lactate dehydrogenase.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 322 references

Cited by

See all 144

Metadata

Authors
Zhang, Y., Li, Q., Huang, Z., Li, B., Nice, E. C., Huang, C., Wei, L., & Zou, B.
Affiliations
  • Sichuan University (CN)
  • Monash University (AU)
  • Weifang Medical University (CN)
Corresponding author
  • Wei, Liuya
  • Zou, Bingwen
Venue
Cancers
Publisher
MDPI AG
Published
2022-09-21
Volume
14
Issue
19
Pages
4568
ISSN
2072-6694 (ISSN-L)
OpenAlex
W4296991129
Cited by
144
References
322
Citations by year
2026: 21 · 2025: 54 · 2024: 40 · 2023: 28 · 2022: 1
FWCI
3.71
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Clinical Research Incubation Project, West China Hospital, Sichuan University (2021HXFH022, 22GJHZ0015, YXJL-2021-1009-0660, ZYGD22007, 82130082)
  • Science and Technology Department of Sichuan Province (2021HXFH022, 22GJHZ0015, YXJL-2021-1009-0660, ZYGD22007, 82130082)
  • Beijing Medical Award Foundation (2021HXFH022, 22GJHZ0015, YXJL-2021-1009-0660, ZYGD22007, 82130082)
  • 1·3·5 project for disciplines of excellence (2021HXFH022, 22GJHZ0015, YXJL-2021-1009-0660, ZYGD22007, 82130082)
  • National Natural Science Foundation of China (2021HXFH022, 22GJHZ0015, YXJL-2021-1009-0660, ZYGD22007, 82130082)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
glucose metabolism reprogramming, glucose metabolism enzymes, cancer metabolism, anticancer drug development, metabolic therapy, natural products, small molecule modulators, combination therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting Glucose Metabolism Enzymes in Cancer Treatment: Current and Emerging Strategies. https://app.cochat.ai/papers/10.3390/cancers14194568
The paper
Zhang, Y., Li, Q., Huang, Z., Li, B., Nice, E. C., Huang, C., Wei, L., & Zou, B. (2022). Targeting Glucose Metabolism Enzymes in Cancer Treatment: Current and Emerging Strategies. Cancers. https://doi.org/10.3390/cancers14194568

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.